- Trials with a EudraCT protocol (25)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
25 result(s) found for: Chemotherapy-Induced Peripheral Neuropathy.
Displaying page 1 of 2.
EudraCT Number: 2006-002917-11 | Sponsor Protocol Number: A0081124 | Start Date*: 2006-11-02 | |||||||||||
Sponsor Name:Pfizer Pharma GmbH | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE PREVENTION AND TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY SYMPTOMS WITH PREGABALIN IN SUBJECTS WITH ADVANCED COLORECTAL CANCER | |||||||||||||
Medical condition: CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY SYMPTOMS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004499-38 | Sponsor Protocol Number: CCR 3116 | Start Date*: 2010-04-16 | |||||||||||
Sponsor Name:Royal Marsden NHS Foundation Trust | |||||||||||||
Full Title: A randomised double-blind placebo-controlled trial of the safety and efficacy of ethosuximide 250mg capsules for the management of chemotherapy-induced painful peripheral neuropathy. | |||||||||||||
Medical condition: The medicial condition under investigation is chemotherapy-induced painful peripheral neuropathy (CIPPN). CIPPN is a complication of several classes of chemotherapy agents e.g taxanes (paclitaxel, ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004033-13 | Sponsor Protocol Number: EMA401-005 | Start Date*: 2012-02-06 | |||||||||||
Sponsor Name:Spinifex Pharmaceuticals Pty Ltd | |||||||||||||
Full Title: A Phase 2 open label biomarker study of angiotensin II type 2 receptor antagonist EMA401 for the treatment of pain in patients with chemotherapy-induced peripheral neuropathy. | |||||||||||||
Medical condition: Chemotherapy induced peripheral neuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003968-31 | Sponsor Protocol Number: | Start Date*: 2014-04-09 | |||||||||||
Sponsor Name:University of Edinburgh (ACCORD) [...] | |||||||||||||
Full Title: A phase II RCT of topical menthol gel versus placebo in the treatment of chemotherapy induced peripheral neuropathic pain | |||||||||||||
Medical condition: Chemotherapy Induced Peripheral Neuropathy (CIPN) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003561-17 | Sponsor Protocol Number: 750CNP01 | Start Date*: 2020-01-23 | |||||||||||
Sponsor Name:Toray Industries, Inc. | |||||||||||||
Full Title: A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TRK-750 in Colorectal Cancer Patients with Chemotherapy-induced Peripheral Neuropathy Following Oxaliplatin-con... | |||||||||||||
Medical condition: Chemotherapy-induced peripheral neuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000821-37 | Sponsor Protocol Number: O3NPIQ | Start Date*: 2019-12-10 | |||||||||||
Sponsor Name:Bernardino Clavo - Hospital Universitario de G. C. Dr. Negrín | |||||||||||||
Full Title: Effectiveness and cost-effectiveness of Ozone therapy in patients with pain secondary to chemotherapy-induced peripheral neuropathy. Randomized, triple-blind clinical trial. | |||||||||||||
Medical condition: Pain secondary to chemotherapy-induced peripheral neuropathy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001218-26 | Sponsor Protocol Number: TRO19622 CL E Q 1204-1 | Start Date*: 2008-06-19 | |||||||||||
Sponsor Name:TROPHOS SA | |||||||||||||
Full Title: A double blind, placebo controlled study of the effect of 330mg QD of TRO19622 in the treatment of Chemotherapy Induced Peripheral Neuropathy. | |||||||||||||
Medical condition: Symptoms of chemotherapy induced peripheral neuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002320-25 | Sponsor Protocol Number: UC_0106/1712 | Start Date*: 2018-07-03 |
Sponsor Name:UNICANCER | ||
Full Title: Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: A phase II randomized study by the UNICANCER with cooperation of AFSOS. | ||
Medical condition: Colorectal cancer stage II/III with adjuvant oxaliplatin-based chemotherapy (simplified FOLFOX4) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000398-21 | Sponsor Protocol Number: ESTEVE-SIGM-202 | Start Date*: 2012-06-21 | |||||||||||
Sponsor Name:Laboratorios del Dr. Esteve, S.A. | |||||||||||||
Full Title: A proof-of-concept phase 2, randomized, placebo-controlled, double blind, multicentre clinical trial in 2 parallel groups to evaluate the efficacy and safety of E-52862 for reducing the incidence a... | |||||||||||||
Medical condition: OXL-induced chronic neuropathy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000435-23 | Sponsor Protocol Number: ATX01-22-01-CIPN | Start Date*: 2022-07-26 | |||||||||||
Sponsor Name:AlgoTherapeutix | |||||||||||||
Full Title: A multicenter, randomized, double-blind, parallel group, placebo controlled, Phase 2 study to assess the efficacy and safety of ATX01 (topical amitriptyline hydrochloride 10% and 15% w/w) in compar... | |||||||||||||
Medical condition: chemotherapy-induced peripheral neuropathy (CIPN) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) CZ (Completed) ES (Ongoing) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003427-36 | Sponsor Protocol Number: M10-898 | Start Date*: 2012-04-12 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: Randomized, Double-Blind, Multicenter, Phase 2 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advance... | |||||||||||||
Medical condition: Metastatic or Advanced Non-Small-Cell Lung Cancer (NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) HU (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004754-42 | Sponsor Protocol Number: PP06490 | Start Date*: 2019-01-22 | |||||||||||
Sponsor Name:PledPharma AB | |||||||||||||
Full Title: A Phase 3, double-blind, multicenter, placebo-controlled study of PledOx used on top of modified FOLFOX6 (5 FU/FA and Oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN) in pa... | |||||||||||||
Medical condition: Chemotherapy induced peripheral neuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) DE (Completed) FR (Completed) ES (Temporarily Halted) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005872-41 | Sponsor Protocol Number: QTZ-EC-0004 | Start Date*: 2012-04-25 | |||||||||||
Sponsor Name:Astellas Pharma Europe Ltd. | |||||||||||||
Full Title: QUTENZA versus pregabalin in subjects with peripheral neuropathic pain: an open-label, randomized, multicenter, noninferiority efficacy and tolerability study | |||||||||||||
Medical condition: Patients who have a documented diagnosis of probable or definite Peripheral Neuropathic Pain | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) CZ (Completed) FI (Completed) AT (Completed) SK (Completed) ES (Completed) BE (Completed) SI (Completed) GB (Completed) DE (Completed) GR (Completed) PT (Completed) IT (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004707-43 | Sponsor Protocol Number: PP06489 | Start Date*: 2018-08-09 | |||||||||||
Sponsor Name:PledPharma AB | |||||||||||||
Full Title: A Phase 3, double-blind, multicenter, placebo-controlled study of PledOx used on top of modified FOLFOX6 (5-FU/FA and Oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN) in th... | |||||||||||||
Medical condition: Chemotherapy induced peripheral neuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) DE (Completed) GB (Completed) ES (Temporarily Halted) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001508-38 | Sponsor Protocol Number: ST 200-DM-03-005 | Start Date*: 2006-03-21 | |||||||||||
Sponsor Name:SIGMA-TAU | |||||||||||||
Full Title: Phase II Explorative Study of Acetyl-L-Carnitine (ST 200) for Vincristine-Induced Neurotoxicity in Patients With Acute Lymphoblastic Leukemia (ALL). | |||||||||||||
Medical condition: Treatment of peripheral sensitive neuropathy vinca alkaloid chemotherapy -induced. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000257-39 | Sponsor Protocol Number: PM60184-B-002-17 | Start Date*: 2017-12-01 | |||||||||||
Sponsor Name:Pharma Mar, S.A. | |||||||||||||
Full Title: A Phase II, Open-label, Multicenter Study of PM060184 in Patients with Advanced Colorectal Cancer after Standard Treatment | |||||||||||||
Medical condition: Advanced Colorectal Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001367-76 | Sponsor Protocol Number: PP095 | Start Date*: 2012-07-18 | |||||||||||
Sponsor Name:PledPharma AB | |||||||||||||
Full Title: A double blinded, randomized, multi centre, three armed phase II trial of PledOx in two different doses in combination with FOLFOX6 compared to placebo + FOLFOX6 in patients with metastatic colorec... | |||||||||||||
Medical condition: Metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) PT (Completed) DE (Completed) BG (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004897-40 | Sponsor Protocol Number: GABA-2 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:PHARM – Pharmaceutical Research Management srl | |||||||||||||
Full Title: Randomized, double-blind, placebo controlled, multi-centre, superiority phase II study to evaluate the safety, pharmacokinetic, efficacy of gabapentin liquid formulation as add-on to morphine in ch... | |||||||||||||
Medical condition: Chronic pain of neuropathic or mixed origin | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) FR (Ongoing) NL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001038-32 | Sponsor Protocol Number: 8-55-58102-002 | Start Date*: 2012-09-07 |
Sponsor Name:Ipsen Pharma | ||
Full Title: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PROOF OF CONCEPT STUDY OF MAINTENANCE THERAPY WITH TASQUINIMOD IN PATIENTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER WHO ARE NOT PROGRESSING... | ||
Medical condition: maintenance therapy in metastatic Castrate Resistant Prostate Cancer patients who are not progressing under/after a first line docetaxel based chemotherapy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: ES (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) LT (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended) DK (Prematurely Ended) GB (Prematurely Ended) DE (Completed) PL (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2017-004034-29 | Sponsor Protocol Number: A206T-G01-001 | Start Date*: 2018-12-19 | |||||||||||
Sponsor Name:Advanced Accelerator Applications International SA | |||||||||||||
Full Title: A Phase I/II open-label, multi-center, dose-escalation study of safety, tolerability, pharmacokinetics, dosimetry, and response to repeat dosing of 177Lu-PSMA-R2 radio-ligand therapy in patients wi... | |||||||||||||
Medical condition: Patients with PSMA positive Metastatic Castration-resistant Prostate Cancer (mCRPC), and disease progression following previous systemic treatment for mCRPC. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
